Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14869MR)

This product GTTS-WQ14869MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14869MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13595MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ13476MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ1462MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ11973MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ15344MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ14842MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ13718MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ8922MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW